Search research articles

关于 JoVE

概览领导团队博客 JoVE 帮助中心

作者

出版流程编辑委员会范围与政策同行评审常见问题投稿

图书馆员

用户评价订阅访问资源图书馆顾问委员会常见问题

研究

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments 存档

教育

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual 教师资源中心教师网站

使用条款与条件

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序

Same author

Making space and opportunities for talent to grow.

JHEP reports : innovation in hepatology·2026

Same author

Preclinical evaluation of [<sup>18</sup>F]fluoroethylresorufin as PET tracer for cerebral amyloid angiopathy.

EJNMMI research·2026

Same author

Concurrent administration of BCMA and GPRC5D chimeric antigen receptor (CAR) T cells in advanced multiple myeloma.

Blood·2026

Same author

Pyraclostrobin impairs metabolic activity and phosphorus uptake of the extraradical mycelium of Rhizophagus intraradices more severely than iprodione.

Mycorrhiza·2026

Same author

Imaging the hallmarks of cancer.

Nature reviews. Cancer·2026

Same author

Pharmacological activation of NO-cGMP signalling attenuates metabolic dysfunction-associated steatohepatitis.

British journal of pharmacology·2026

Search research articles

相关实验视频

Updated: Jan 13, 2026

Author Spotlight: Enhancing CAR-T Cell Function in Syngeneic Tumor Models

Author Spotlight: Enhancing CAR-T Cell Function in Syngeneic Tumor Models

Published on: February 2, 2024

适应CAR的PIK3CD基编辑增强了T细胞的抗瘤功效.

Philip Bucher^1,2, Nadine Brückner^1,3, Jule Kortendieck^1,3

¹Cluster of Excellence iFIT (EXC2180) 'Image-guided and Functionally Instructed Tumor Therapies', University of Tübingen, Tübingen, Germany.

|January 6, 2026

概括

基编辑通过微调酸-3-激酶三角酶 (PI3Kδ) 信号,优化了仿真抗原受体 (CAR) T 细胞. 特定突变增强了CAR T细胞的持久性和治疗癌症治疗的疗效.

更多相关视频

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Published on: May 9, 2025

相关实验视频

Last Updated: Jan 13, 2026

Author Spotlight: Enhancing CAR-T Cell Function in Syngeneic Tumor Models

Author Spotlight: Enhancing CAR-T Cell Function in Syngeneic Tumor Models

Published on: February 2, 2024

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Published on: May 9, 2025

科学领域:

免疫学免疫学免疫学
细胞生物学细胞生物学
生物技术是生物技术.

背景情况:

化学抗原受体 (CAR) T细胞疗法显示出希望,但由于T细胞持续性不足而受到限制.
T细胞的功能,新陈代谢和命运是由酸-3-酶三角酶 (PI3Kδ) 调节的.

研究的目的:

用基编辑屏幕识别PIK3CD中有利于增强CAR T细胞功能和持久性的点突变.
研究PI3Kδ信号调制对不同类型的CAR T细胞 (4-1BBz和28z) 的影响.

主要方法:

进行了针对PIK3CD的CAR适应的基础编辑屏幕.
在CAR T细胞中引入了特定的PIK3CD点突变 (E81K和L32P).
评估了CAR T细胞的增殖,新陈代谢,效应器功能和记忆形成.

主要成果:

激活PI3Kδ的突变E81K增强了4-1BBzCAR T细胞的增殖,代谢适应性和效应器功能,改善了体内疗效和持久性.
减弱PI3Kδ的突变L32P改善了28zCAR T细胞的记忆形成和功能.
通过有针对性的等位基重编程 (ROADSTAR) 证明了CAR设计特异性的T细胞信号微调.

结论:

基编辑可以用于优化CAR T细胞特性,以提高治疗效果.
通过特定突变定制PI3Kδ信号,可以改善不同CAR T细胞的功能.
ROADSTAR方法为开发下一代细胞疗法提供了一个强大的策略.